AMAG Pharmaceuticals Appoints Robert F. Kaper, M.D. as Senior Vice President of Medical and Scientific Affairs

AMAG Pharmaceuticals Appoints Robert F. Kaper, M.D. as Senior Vice President
of Medical and Scientific Affairs

WALTHAM, Mass., Oct. 29, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc.
(Nasdaq:AMAG) today announced the appointment of Robert F. Kaper, M.D. to the
role of senior vice president of medical and scientific affairs (recently
vacated). Dr. Kaper brings to AMAG more than 20 years of healthcare experience
in the global biopharmaceutical industry. Prior to joining AMAG, Dr. Kaper
served in executive medical affairs roles at Teva Pharmaceuticals, Cephalon,
and Organon.

"We welcome Rob to AMAG and look forward to his leadership of our medical and
scientific initiatives and our medical affairs team," said William Heiden,
president and chief executive officer of AMAG. "Rob's wealth of experience
will be a tremendous asset as we formulate and implement medical affairs
strategies to further our mission of supporting optimal patient care by
offering education and scientific/medical information to physicians and
nurses. The AMAG team looks forward to his contributions on our current
products, and future in-licensed or acquired products."

"I am very pleased to be joining AMAG at this time, with many exciting
opportunities ahead for the company," said Dr. Kaper."I look forward to
working with my new team to plan and execute the medical and scientific
support of Feraheme, MuGard and additional future products."

Dr. Kaper has significant experience in global medical affairs in the areas of
neurology, oncology, immunology, women's health and pain management.He has
held leadership roles in medical affairs both in the U.S. and globally. Dr.
Kaper has successfully formulated strategic clinical development plans,
implemented life cycle management programs and supported the commercialization
of new products.A native of the Netherlands, Dr. Kaper received his medical
degree from the Free University in Amsterdam with postgraduate training in
neurosurgery at the Slotervaart Hospital and orthopedic surgery at the
Academic Hospital of the Free University in Amsterdam.

Inducement Equity Awards

In connection with Dr. Kaper's entry into his employment agreement, effective
on the first day of employment, Dr. Kaper will be granted (i) an option to
purchase 60,000 shares of common stock and (ii) 20,000 restricted stock units.
The option will have an exercise price equal to the closing price of AMAG's
common stock on the grant date and will be exercisable in four equal annual
installments beginning on the first anniversary of the grant date. The option
will have a ten-year term and be subject to the terms and conditions of the
stock option agreement pursuant to which the option will be granted. The
restricted stock units will vest in four equal annual installments beginning
on the first anniversary of the grant date and will be subject to the
restricted stock unit agreement pursuant to which the restricted stock units
will be granted.

These equity awards will be granted without stockholder approval as
inducements material to Dr. Kaper's entering into employment with AMAG in
accordance with NASDAQ Listing Rule 5635(c)(4).

About AMAG

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets
Feraheme® (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound Rinse in
the United States. Along with driving organic growth of its products, AMAG
intends to expand its portfolio with additional commercial-stage specialty
products. The company is seeking complementary products that leverage the
company's commercial footprint and focus on hematology and oncology centers
and hospital infusion centers. For additional company information, please

Forward-looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 and other federal
securities laws. Any statements contained herein which do not describe
historical facts, including but not limited to statements regarding: the
potential approval of the supplemental new drug application Feraheme for a
broader patient population; Dr. Kaper's contributions to AMAG and the intended
expansion and focus of AMAG's product portfolio; the company's intent to drive
organic growth of Feraheme; and the company's plans to seek complementary
commercial products to add to its portfolio are forward-looking statements
which involve risks and uncertainties that could cause actual results to
differ materially from those discussed in such forward-looking statements.

Such risks and uncertainties include: (1) uncertainties regarding our and
Takeda's ability to successfully compete in the intravenous iron replacement
market both in the US and outside the US, including the EU, (2) uncertainties
regarding our ability to compete in the oral mucositis market in the US, (3)
uncertainties regarding our ability to successfully and timely complete our
clinical development programs and obtain regulatory approval for
Feraheme/Rienso in the broader IDA indication both in the US and outside of
the US, including the EU, (4) the possibility that significant safety or drug
interaction problems could arise with respect to Feraheme/Rienso, (5)
uncertainties regarding the manufacture of Feraheme/Rienso or Mugard, (6)
uncertainties relating to our patents and proprietary rights both in the US
and outside the US, (7) the risk of an Abbreviated New Drug Application (ANDA)
filing following the FDA's recently published draft bioequivalence
recommendation for ferumoxytol, and (8) other risks identified in our
Securities and Exchange Commission (SEC) filings, including our Quarterly
Report on Form 10-Q for the year ended June 30, 2013 and subsequent filings
with the SEC. We caution you not to place undue reliance on any
forward-looking statements, which speak only as of the date they are made.

We disclaim any obligation to publicly update or revise any such statements to
reflect any change in expectations or in events, conditions or circumstances
on which any such statements may be based, or that may affect the likelihood
that actual results will differ from those set forth in the forward-looking

AMAG Pharmaceuticals and Feraheme are registered trademarks of AMAG
Pharmaceuticals, Inc. Rienso is a registered trademark of Takeda
Pharmaceutical Company Limited. MuGard is a registered trademark of Access
Pharmaceuticals, Inc.

CONTACT: AMAG Pharmaceuticals, Inc.
         Amy Sullivan, 617-498-3303

AMAG Pharmaceuticals logo
Press spacebar to pause and continue. Press esc to stop.